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Introduction: Rivaroxaban is an oral, selective direct factor Xa inhibitor approved for several indications in pa-
tients at risk of thrombotic events. One limitation of its clinical use is the lack of data pertaining to its reversal
in situations where urgent response is critical (e.g. acute bleeding events or emergency surgery).
Materials and methods: This study assessed the effectiveness of a four-factor prothrombin complex concentrate
(4F-PCC; Beriplex®/Kcentra®) for the reversal of rivaroxaban-associated bleeding in an in vivo rabbit model,
and evaluated the correlations between in vitro coagulation parameters and haemostasis in vivo.
Results: Administration of single intravenous doses of rivaroxaban (150–450 μg/kg) resulted in increased and
prolonged bleeding following standardised kidney incision. Pre-incision treatmentwith 4F-PCC (25–100 IU/kg) re-
sulted in a dose-dependent reversal of rivaroxaban (150 and 300 μg/kg)-associated increases in time to
haemostasis and blood loss; no reversal was seen at the highest rivaroxaban dose (450 μg/kg). Of the in vitro
biomarkers tested, thrombin generation and whole-blood clotting time correlated well with in vivomeasures of
4F-PCC-mediated effects. Thrombin generation was highly reagent-dependent, with the assay initiated using the
phospholipid-only reagent being the most predictive of effective haemostasis in vivo.
Conclusions: In summary, in a rabbit model of acute bleeding, treatment with 4F-PCC reduced bleeding to control
levels following rivaroxaban 150 μg/kg and 300 μg/kg administration.© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Acting at the point of convergence of the intrinsic and extrinsic coag-
ulation pathways, factor Xa (FXa) is a serine protease that plays a key
role in the coagulation cascade by converting prothrombin to thrombin
[1,2]. These features of FXamake it a target for the development of new
anticoagulants, and in recent years several new direct oral FXa inhibi-
tors have been licensed for a number of indications related to the pre-
vention of thrombotic events. Rivaroxaban (Bayer HealthCare AG,
Leverkusen, Germany), one of these FXa inhibitors, is currently
approved for the prevention of stroke and systemic embolism in pa-
tients with non-valvular atrial ﬁbrillation (AF), the treatment of deep
vein thrombosis (DVT) and pulmonary embolism (PE), the prevention
of recurrent DVT and PE, DVT prophylaxis in patients undergoing hip49 6421 394663.
og),
ge@cslbehring.com (W. Krege),
baerbel.doerr@cslbehring.com
.dickneite@cslbehring.com
. This is an open access article underor knee surgery, and the prevention of atherothrombotic events after
an acute coronary syndrome [3].
While newer oral anticoagulants (NOACs), such as rivaroxaban, do
not require routine monitoring owing to their predictable pharmacoki-
netic and pharmacodynamic proﬁles, this may still be helpful in emer-
gency situations (e.g. prior to an emergency surgery or in the case of a
life-threatening bleeding event), when assessment of bleeding risk
and subsequent rapid anticoagulation reversal is critical. Clinical studies
of rivaroxaban demonstrated a good correlation between rivaroxaban
plasma levels and inhibition of FXa activity or prolongation of the pro-
thrombin time (PT) [4–6]. However, other standard coagulation assays
(e.g. activated partial thromboplastin time [aPTT], thrombin time [TT],
ecarin clotting time [ECT]) may be of less relevance for monitoring the
anticoagulant effects of rivaroxaban [6,7].
Despite the advantages offered by rivaroxaban over traditional anti-
coagulants, bleeding complications (including spontaneous and periop-
erative bleeding) remain a signiﬁcant concern for clinicians. This
concern is further compounded by the lack of validated reversal strate-
gies for direct FXa inhibitors at present [8,9]. Based on data from clinical
trials that compared NOACs and warfarin in patients with AF, the rates
of major bleeding events appear to be in a similar range in NOAC- or
warfarin-treated patients (2.1–3.6% versus 3.1–3.4%, respectively)the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
In vivo study: treatment group assignment.
Rivaroxaban dose
(μg/kg)
4F-PCC dose
(IU/kg)
Animals
(n)
0a 0b 5
150 0b 5
150 25 5
300 0b 5
300 25 5
300 50 5
300 100 5
450 0b 5
450 50 5
450 100 5
avehicle (polyethylene glycol/water/ethanol 50%/40%/10% solution) administered;
bisotonic saline 0.9% (w/v) administered; rivaroxaban was administered at t = 0 min,
4F-PCCwas administered at t = 3min. 4F-PCC, four-factor prothrombin complex concen-
trate; IU, international unit.
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associated bleeding events in real-world clinical practice. Taking into
account the growing number of patients receiving NOACs, there is an
urgent need for strategies to manage these challenging clinical situa-
tions. Owing to the relatively short half-lives of NOACs, interruption
of treatment may be sufﬁcient in most non-emergency situations
(e.g. prior to elective surgery or in patients with minor bleeding) [14,
15]. However, in cases of life-threatening bleeding, or when urgent
anticoagulation reversal is required (e.g. prior to emergency surgery),
current guidelines suggest administering haemostatic agents, such as
recombinant activated factor VII (rFVIIa) or activated/non-activated
prothrombin complex concentrates (PCCs) [14–21]. Owing to their po-
tentially lower prothrombotic potential, non-activated PCCs may be
preferable to rFVIIa and activated PCCs [21,22].
The aimof this studywas to evaluate the potential of a non-activated
four-factor PCC (4 F-PCC; Beriplex® [known as Kcentra® in the USA];
CSL Behring GmbH, Marburg, Germany) to reverse the effects of
rivaroxaban in an in vivo rabbit model. As well as investigating treat-
ment effects on blood loss and time to haemostasis following acute in-
jury, this study aimed to evaluate the correlations between in vitro
coagulation assays and in vivomeasures of haemostasis, and determine
which coagulation assay would best predict the effectiveness of 4 F-PCC
treatment for reversal of rivaroxaban-associated bleeding.
Materials and Methods
The study was conducted using a rabbit model previously utilised to
assess dabigatran and edoxaban reversal [23,24]. Study animals re-
ceived care in compliance with the European Convention on Animal
Care and procedures were approved by the local animal welfare
authority.
Study Agents
4 F-PCC (Beriplex® [known as Kcentra® in the USA]; CSL Behring
GmbH,Marburg, Germany), containing factors II, VII, IX and X and coagu-
lation proteins C and S [25], was reconstituted in water for injection at
room temperature and used immediately. The diluent was injected into
the 4 F-PCC vial at an appropriate volume to obtain a ﬁnal concentration
of 28 IU/mL, as instructed by the label. Rivaroxaban (BayerHealthCareAG,
Leverkusen, Germany) was dissolved in a solution of polyethyleneglycol
(PEG) 400/H2O/ethanol (50%/40%/10%) (CSL Behring GmbH, Marburg,
Germany). To achieve a clear solution at the 1.0mg/mL dose, the solution
was warmed to 37 °C and placed in an ultrasound bath for 60 min.
Study Endpoints
The main objective of this unblinded, randomised rabbit study was
to evaluate in vivo the ability of a 4 F-PCC to reverse the effects of
rivaroxaban in an acute bleedingmodel. In addition to the primary end-
points of time to haemostasis and volumeof blood loss, this in vivo study
evaluated treatment effects on the following coagulation parameters:
PT, aPTT, whole-blood clotting time (WBCT) and thrombin generation
using different reagents. Rivaroxaban plasma levels were assessed
based on FXa inhibition.
Animals
Female Chinchilla Bastard rabbits, 3–4 months of age, weighing
2.5–3.2 kg, were obtained from Bauer (Neuental, Germany) and housed
individually in wire-steel cages at 21− 23 °C and 50% relative humidity
under a 12 h/12 h light/darkness cycle. The animals had free access to
tapwater andwere fed rabbit pellets (Deukanin, Deutsche Tiernahrung
Cremer GmbH & Co. KG, Düsseldorf, Germany) ad libitum. The animal
groups were distributed within and between racks in a manner that
allowed equalisation of environmental inﬂuences across the study.Treatment
The full details of treatment group assignment are described in
Table 1. Animals were assigned to 10 groups (n = 5 animals per
group). Sample size for the treatment groups were chosen to allow
statistical analysis of the results obtained based on previous experi-
ence ofNOAC reversal in this rabbit model. Animals received a single
intravenous (iv) administration of increasing doses of reconstituted
rivaroxaban (150, 300 and 450 μg/kg) with the aim of inducing a
clear bleeding signal after kidney incision; the vehicle control group
received vehicle solution instead of rivaroxaban. At 3 min after
rivaroxaban administration, the animals received an iv administration
of 4 F-PCC at dose levels of 25, 50 and 100 IU/kg or an iv bolus of an
equal volume of 0.9% (w/v) isotonic saline instead of 4F-PCC. Doses
of 4 F-PCC were selected based on the recommended clinical dose
for VKA reversal (maximumdose 50 IU/kg) [24] andmultiples thereof.
Anaesthesia
Anaesthesia was induced using 4.5–8.5 mg/kg iv ketamine and
0.5–1.1 mg/kg iv xylazine 2%. Animals were intubated and ventilated
over the study period; inhaled anaesthesia was maintained using
isoﬂurane (Isoﬂuran CP®, CP-Pharma Handelsgesellschaft mbH,
Burgdorf, Germany). Following a 20-min stabilisation period, a carotid
artery catheter (22G needle; B Braun, Melsungen, Germany), ﬁxed by
a ligature around the artery, was used for blood sampling purposes.
The catheter was ﬂushed with saline after each blood sampling.
Kidney Incision
A standardised kidney incision was performed as described previ-
ously [23]. Brieﬂy, at 5 min after 4 F-PCC infusion (8 min post
rivaroxaban administration), a standardised kidney incision (measuring
15 mm long and 5 mm deep) was created, using a scalpel, from the
upper to the lower kidney poles. The 30-min observation period for
the assessment of blood loss and time to haemostasis began immediate-
ly after the kidney incision.
Assessments
Blood samples for determination of rivaroxaban plasma levels and
coagulation parameters were collected at baseline, after rivaroxaban
administration but prior to 4 F-PCC administration (t = 3 min),
after 4 F-PCC administration and immediately before kidney incision
(t = 8 min) and at the end of the observation period (t = 40 min).
Approximately 1.65 mL of blood was drawn at each time point and col-
lected in a 5 mL single-use polystyrol tube. A whole blood sample of
0.50 mL was used to determine the WBCT. The remainder was
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Fig. 1. Rivaroxaban plasma levels Number of replicates = 5.
556 E. Herzog et al. / Thrombosis Research 135 (2015) 554–560processed to 10% citrate plasma and split into aliquots: two aliquots
of 0.20 mL were used to determine thrombin generation, two aliquots
of 0.25 mL were used to ascertain aPTT and PT, and one aliquot of
0.25 mL was used to assess FXa inhibitor activity.
Blood Loss
Blood losswasmeasured as the volume of blood collected by syringe
from the kidney-incision site.
Time to Haemostasis
Time to haemostasis was deﬁned as the time that elapsed between
kidney incision and cessation of observable bleeding or oozing.
Rivaroxaban Plasma Levels
Rivaroxaban plasma levels were evaluated using FXa inhibition, as
determined by a colourimetric test (STA-Liquid Anti-Xa, Diagnostica
Stago S.A.S., Asnières sur Seine, France) using a Behring Coagulation
System® (Siemens AG, Erlangen, Germany).
PT and aPTT
Assays of PT and aPTT were performed using a Behring Coagulation
System® (Siemens AG), and the Thromborel S (Siemens Healthcare
Diagnostics, Eschborn, Germany) and actin FSL reagents (Siemens
Healthcare Diagnostics), respectively.
WBCT
WBCT was determined manually in a glass vial kept at 37 °C in a
water bath by assessing the time to formation of a visible clot.
Thrombin Generation
Thrombin generation was assessed using a calibrated Automated
Thrombogram in platelet-poor plasma. The assay was conducted using
two different reagents to initiate thrombin generation: phospholipids
containing 5 pM tissue factor (TF) (Diagnostica Stago S.A.S.) for extrin-
sic activation, or phospholipids only (RD Technothrombin® TGA,
Technoclone, Vienna, Austria) for intrinsic activation.
Statistical Analysis
Mean (SD) or median (range) are reported. Time to haemostasis and
volume of blood loss were compared between 4 F-PCC dose groups at
identical rivaroxaban doses by the likelihood ratio test for censored
log-normally distributed data. With the same distributional assump-
tions, time to haemostasis and volume of blood loss were regressed on
rivaroxaban plasma levels, PT, aPTT,WBCT, and thrombin generation pa-
rameters. The p-values of the regression coefﬁcients were computed by
transforming the likelihood ratio statistic Λ to an approximate F-variate
with 1 and (n*− 2) degrees of freedom: F = (n*− 2)(exp(Λ/n*)− 1)
where n* is the effective sample size [26]. Conversely, PT, aPTT, WBCT,
and thrombin generation parameters were linearly regressed on
rivaroxaban plasma levels and p-values of the regression coefﬁcients
were provided. The individual data of the regression models are graphi-
cally displayed. Some jittering of the plotting positions was applied to
avoid overlaying data points. The dependence between explanatory var-
iable and outcome variable was visualised by ﬁtting smoothing splines
(ignoring censoring, if any).
Statistical analysis was performed with SAS/STAT® version 9.4.
Results were documented using GraphPad Prism® version 5.04.
Results
Pharmacokinetics and Pharmacodynamics
Following a single iv bolus of rivaroxaban (150–450 μg/kg), a dose-
dependent increase in exposure was observed. Mean (SD) maximumplasma levels (measured at 3 min post dosing, i.e. at the ﬁrst sampling
time point) were 142 (54), 281 (69) and 485 (58) ng/mL for the
150, 300 and 450 μg/kg doses, respectively; plasma levels rapidly
declined thereafter (Fig. 1). The maximum plasma levels measured for
the 300 μg/kg dose were similar to that achieved for the 20 mg maxi-
mum recommended clinical dose in humans (Cmax 249–270 ng/mL)
[4], while the maximum plasma levels measured for the 450 μg/kg
dose corresponded to about twice the human plasma levels following
a 20 mg dose.
Plasma levels of coagulation factors II, VII, IX and X following a single
iv bolus of 4 F-PCC have been assessed in a previous study [24]; this
analysis was not repeated here.
Effects on Bleeding Diathesis
In the vehicle control group, themedian (range) total blood loss and
time to haemostasis were 5.0 (4–6) mL and 6.0 (3–7) min, respectively
(Fig. 2). This is comparable to values previously reported in a similar
animal model (1.0–7.2 mL and 1.8–6.0 min for blood loss and time to
haemostasis, respectively) [23].
A single iv administration of rivaroxaban (150, 300 or 450 μg/kg)
markedly increased both time to haemostasis and total blood loss fol-
lowing standardised kidney incision (Fig. 2). While dose-dependency
was seen between the 150 and 300 μg/kg doses, both rivaroxaban 300
and 450 μg/kg resulted in time to haemostasis ≥30 min (therefore ex-
ceeding the observation period) in all but one animal (Fig. 2A), and sim-
ilar total blood loss volumes (median [range]: 20 [18–50] mL and 21
[16–45] mL, respectively) (Fig. 2B). There was a correlation between
the rivaroxaban plasma levels determined based on FXa inhibition and
the bleeding signals observed (p b 0.0001 for time to haemostasis and
p = 0.0002 for blood loss).
Subsequent iv administration of 4 F-PCC (25–100 IU/kg) at 3 min
post rivaroxaban administration dose-dependently reversed the
increases in bleeding parameters induced by rivaroxaban 150 and
300 μg/kg (Fig. 2). In the rivaroxaban 300 μg/kg group, administration
of 50 IU/kg 4 F-PCC reduced time to haemostasis to a median (range)
of 10 (6–19) min (63% reduction; p = 0.0021; Fig. 2A), and total blood
loss to a median (range) of 5 (5–13) mL (77% reduction; p = 0.0008;
Fig. 2B), compared with the control rabbits (no 4 F-PCC administered).
Effects on blood loss and time to haemostasis induced by the highest
rivaroxaban dose (450 μg/kg) could not be reversed by 4 F-PCC (Fig. 2).
Biomarkers of Haemostasis
Coagulation Parameters: PT, aPTT and WBCT
Rivaroxaban treatment resulted in the prolongation of all three co-
agulation parameters tested. As reported elsewhere [4,5], there was
a strong correlation between PT and rivaroxaban plasma levels
(p b 0.0001; Fig. 3A). The WBCT also correlated well with plasma
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Fig. 2. Treatment effects on time to haemostasis (A) and blood loss (B). Animals in the rivaroxaban 0 μg/kg groups received vehicle (polyethylene glycol/water/ethanol 50%/40%/10% so-
lution) instead of rivaroxaban; animals in the 4 F-PCC 0 IU/kg groups received isotonic saline 0.9% (w/v) instead of 4F-PCC. Horizontal bars represent minimum, median, and maximum;
*p b 0.05, **p b 0.01, ***p b 0.001 versus control group (no 4 F-PCC administered). 4F-PCC, four-factor prothrombin complex concentrate; IU, international unit.
557E. Herzog et al. / Thrombosis Research 135 (2015) 554–560levels of rivaroxaban (p b 0.0001; Fig. 3C), although a plateau was ob-
served for WBCT at rivaroxaban plasma levels ≥300 ng/mL. The corre-
lation between aPTT and rivaroxaban plasma levels was not as strong
as that of PT and WBCT, but was still signiﬁcant (p = 0.0028; data
not shown).
The 4F-PCC-mediated reductions in time to haemostasis were not,
however, reﬂected by aPTT (p = 0.15; data not shown). In animals re-
ceiving rivaroxaban only, mean (SD) aPTT values dose-dependently in-
creased from 20.52 (2.20) s in the negative control group up to a
maximum of 37.48 (4.59) s at 8 min post 450 μg/kg rivaroxaban treat-
ment (Table 2). Subsequent administration of 4 F-PCC was not able to
reduce aPTT levels, independent of the rivaroxaban and 4 F-PCC doses
applied (Table 2). There was also no correlation between aPTT and
total blood loss (data not shown).
4 F-PCC treatment partially reversed rivaroxaban-induced PT pro-
longation and there was a trend for a correlation between PT values
and time to haemostasis, although this was not signiﬁcant (p = 0.07;
Fig. 3B). The correlation between PT and total blood loss was also not
signiﬁcant (data not shown). In animals receiving rivaroxaban only,
mean (SD) PT values increased from9.50 (0.46) s in thenegative control
group to 16.86 (1.57) s for the rivaroxaban 450 μg/kg dose (Table 2). In
animals treated with rivaroxaban 300 and 450 μg/kg, 4 F-PCC was able
to dose-dependently reduce PT levels; however, full reversal of PT pro-
longation was not achieved (Table 2).
The best correlation with time to haemostasis was seen for WBCT
(p = 0.0001; Fig. 3D). The correlation between WBCT and total blood
loss was also statistically signiﬁcant (data not shown). Rivaroxaban
treatment resulted in a dose-dependent prolongation of WBCT from a
mean (SD) of 174 (22.75) s in the negative control group to 354
(27.25) s at 8 min after administration of rivaroxaban 450 μg/kg
(Table 2).WBCT prolongationwas dose-dependently reduced following
4 F-PCC infusion (Table 2); however, as observed for PT, full normalisa-
tion of WBCT could not be achieved with the 4 F-PCC doses tested
(Table 2).
Thrombin Generation Assay
Results from the thrombin generation assay were found to be
reagent-dependent. Administration of rivaroxaban (150–450 μg/kg)
strongly inhibited extrinsic thrombin generation initiated using TF in
addition to phospholipids, with markedly reduced peak thrombin
generation and endogenous thrombin potential (ETP) (Table 3). These
thrombin generation parameters correlated well with rivaroxaban
plasma levels (p = 0.0005 and p = 0.0062 for peak thrombin genera-
tion and ETP, respectively). Subsequent administration of 4 F-PCC
to animals in the 300 μg/kg rivaroxaban group did not reverserivaroxaban-induced changes in peak thrombin generation and
ETP under these assay conditions (Table 3), despite the positive
4F-PCC-mediated effects on bleeding diathesis previously described in
this treatment group (Fig. 2). No correlation was observed between
peak thrombin generation or ETP (extrinsic activation) and time to
haemostasis (p = 0.18 and p = 0.58, respectively). Similar results
were seen for the correlation between peak thrombin generation or
ETP (extrinsic activation) and total blood loss (data not shown). These
results indicate that these thrombin generation assay conditions may
not be optimal for assessment of 4F-PCC-mediated rivaroxaban reversal.
In contrast, rivaroxaban-induced inhibition of thrombin generation
initiated using the RD reagent (phospholipids only) was less pro-
nounced (Table 3); p-values for the correlation of peak thrombin gener-
ation and ETP (intrinsic activation)with rivaroxabanplasma levelswere
p = 0.0098 and p = 0.0849, respectively (Fig. 3E and G). However,
reversal effects mediated by administration of 4 F-PCC could easily be
detected (p=0.0028 and p=0.0020 for the correlation of peak throm-
bin generation and ETP [intrinsic activation], respectively, with time to
haemostasis [Fig. 3F and H]). The correlations of peak thrombin genera-
tion or ETP (intrinsic activation) with blood loss were also signiﬁcant
(data not shown). Using these assay conditions, the rivaroxaban
300 μg/kg-induced reductions in peak thrombin generation and ETP
were reversed by treatment with 4 F-PCC to levels higher than those
seen for the negative control (Table 3). However, 4F-PCC-mediated re-
versal of the effects of rivaroxaban 450 μg/kg on peak thrombin genera-
tion and ETP was also observed (Table 3), despite the fact that
rivaroxaban 450 μg/kg effects on bleeding diathesis could not be re-
versed by 4 F-PCC (Fig. 2).
Therefore, while extrinsic thrombin generation was more sensitive
to the effects of rivaroxaban treatment on time to haemostasis and
blood loss, initiation of thrombin generation with phospholipids only
was more sensitive to the 4F-PCC-mediated reversal of rivaroxaban-
associated effects on haemostasis in this animal model.
Discussion
This study evaluated the 4F-PCC-mediated reversal of rivaroxaban-
associated bleeding and anticoagulation in a rabbit model. Rivaroxaban
administration markedly increased blood loss and time to haemostasis.
Subsequent administration of 4 F-PCC (25–100 IU/kg) effectively, and
dose-dependently, improved clinical measures of haemostasis follow-
ing a 150 or 300 μg/kg rivaroxaban dose, and was able to return these
clinical markers to control values. The effects on bleeding diathesis in-
duced by the highest dose of rivaroxaban (450 μg/kg) could not be re-
versed by 4 F-PCC at the dose levels administered in this study.
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Fig. 3. Correlation between coagulationmarkers and rivaroxaban plasma levels (A, C, E and G) or time to haemostasis (B, D, F and H). A, B: correlation between PT and rivaroxaban plasma
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Rivaroxaban plasma levels and coagulation/thrombin generation parameters (PT, WBCT, peak thrombin generation, ETP) were measured at t = 8 min. A, C, E, G show data obtained
after treatment with ascending doses of rivaroxaban, but in the absence of 4 F-PCC treatment; p-values refer to the correlation between the coagulation parameter of interest and
rivaroxaban plasma levels. B, D, F, H show data obtained after treatment with 300 μg/kg rivaroxaban and ascending doses of 4 F-PCC; p-values refer to the correlation between time to
haemostasis and the coagulation parameter of interest. Animals in the rivaroxaban 0 μg/kg groups received vehicle (polyethylene glycol/water/ethanol 50%/40%/10% solution) instead
of rivaroxaban; animals in the 4 F-PCC 0 IU/kg groups received isotonic saline 0.9% (w/v) instead of 4F-PCC. 4F-PCC, four-factor prothrombin complex concentrate; ETP, endogenous
thrombin potential; IU, international unit; PT, prothrombin time; WBCT, whole blood clotting time.
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Table 2
Coagulation parameters: treatment effect on PT, aPTT and WBCT.
Rivaroxaban (μg/kg) 4F-PCC (IU/kg) PTa (s) aPTTb (s) WBCT (s)
Mean SD Mean SD Mean SD
0c 0d 9.5 0.5 20.5 2.2 174 23
150 0d 11.0 0.6 31.6 6.8 279 25
150 25 11.9 1.2 35.6 5.8 246 49
300 0d 13.3 1.7 36.2 8.7 345 21
300 25 12.7 1.0 34.7 4.8 312 22
300 50 13.0 0.4 39.8 3.8 291 31
300 100 11.2 0.9 39.0 5.1 219 8
450 0d 16.9 1.6 37.5 4.6 354 27
450 50 14.3 1.5 39.3 3.6 288 34
450 100 11.7 0.5 41.6 4.6 282 47
Coagulation parametersmeasured at t= 8min; values in the table aremean±SD (n=5);
ainitiated using Thromborel S; binitiated using Actin FSL; cvehicle (polyethylene glycol/
water/ethanol 50%/40%/10% solution) administered; disotonic saline 0.9% (w/v)
administered. 4F-PCC, four-factor prothrombin complex concentrate; aPTT, activated
partial thromboplastin time; IU, international unit; PT, prothrombin time; SD, standard
deviation; WBCT, whole blood clotting time.
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dose of rivaroxaban, as the maximum measured rivaroxaban plasma
levels achieved in rabbits with this dose represent approximately
double those seen in humans receiving the maximum clinical dose of
20 mg [4,27].
While NOACs, such as rivaroxaban, provide an effective alternative
to traditional anticoagulation treatment (e.g. warfarin), validated rever-
sal strategies and speciﬁc antidotes still remain to be identiﬁed. Based
on consensus opinion and preclinical data, current guidelines suggest
the use of haemostatic agents, such as PCCs, for the urgent reversal of
NOACs (such as in case of life-threatening bleeding or prior to an urgent
surgical procedure) [14,15,17–21]. However, the use of PCCs for this in-
dication still represents an off-label use and remains to be validated in
NOAC-treated patientswith clinically relevant bleeding.While adminis-
tration of the speciﬁc FXa inhibitor antidote PRT064445 (Portola
Pharmaceuticals Inc., San Francisco, CA, USA) was associated with
dose-dependent reversal of rivaroxaban-associated blood loss in rats
[28], this agent is still in development, such that non-selective
haemostatic agents are still likely to be needed in the clinical setting.
Studies that have assessed the use of haemostatic agents for
rivaroxaban reversal have demonstrated varying results with regards
to both rivaroxaban-induced anticoagulant effect and its reversal [29].
For example, not all preclinical studies have demonstrated the ability
of PCCs to effectively reverse rivaroxaban-associated anticoagulationTable 3
Thrombin generation assay: reagent effect on measures of rivaroxaban anticoagulation
and 4F-PCC-mediated rivaroxaban reversal.
Rivaroxaban
(μg/kg)
4F-PCC
(IU/kg)
TGA extrinsica TGA phospholipids onlyb
Peak (nM) ETP (nM.min) Peak (nM) ETP (nM.min)
Mean SD Mean SD Mean SD Mean SD
0c 0d 148 33.1 577 95.4 273 23.0 869 190.3
150 0d 23 5.6 440 97.5 273 60.8 813 470.8
150 25 16 15.5 552 476.2 299 56.5 1330 391.8
300 0d 19 12.3 409 195.9 216 52.3 594 94.0
300 25 7 1.7 250 77.6 304 32.5 1457 179.0
300 50 9 1.8 356 111.3 333 18.5 3075 1467.2
300 100 7 1.3 334 86.2 371 87.0 2738 436.1
450 0d 12 10.2 271 197.3 218 23.6 641 188.0
450 50 6 5.2 236 104.3 300 99.1 2296 472.2
450 100 4 1.4 120 62.0 413 31.0 2766 1743.0
Thrombin generation measured at t = 8min; values in the table are mean± SD (n= 5);
ainitiated using TF + phospholipids (PPP reagent); binitiated using phospholipids only
(RD reagent); cvehicle (polyethylene glycol/water/ethanol 50%/40%/10% solution) admin-
istered; disotonic saline 0.9% (w/v) administered. 4F-PCC, four-factor prothrombin com-
plex concentrate; ETP, endogenous thrombin potential; IU, international unit; PPP,
platelet poor plasma; TF, tissue factor; TGA, thrombin generation assay.or bleeding [30–32]. In addition, some inconsistencies with regards to
PCC-mediated effects on coagulation parameters have been observed.
For instance, full reversal of rivaroxaban-induced PT prolongation has
been observed in some healthy volunteer studies [33], while others
have shown either only partial [34–36] or no reversal of this parameter
[37]. These differences may be due to inherent differences in study
design, methodology and dose of both oral anticoagulant and reversal
agent used.
Traditional laboratory coagulation assays, originally developed
for VKA monitoring, have varying sensitivity to NOAC-mediated effects
[7,38,39], and therefore may not be optimal for their monitoring. As
observed in this study, previous studies of rivaroxaban reversal have
also demonstrated a lack of robust correlation between reversal of
rivaroxaban-associated bleeding and reversal of rivaroxaban-induced
changes on anticoagulation parameters. For example, while PT has
been found to correlate well with plasma levels of rivaroxaban [4–6],
this and other preclinical studies [40] have found limited correlation be-
tween reversal of rivaroxaban-associated bleeding and reversal of PT
prolongation. WBCT correlated well with plasma rivaroxaban levels
and partially reﬂected 4F-PCC-mediated effects on clinical markers of
haemostasis in this study. Thrombin generation appears to be the
most sensitive assay [29], but the choice of reagent is critical in order
to reliablymeasure reversal. In our study, thrombin generation initiated
using the RD reagent was found to be the most sensitive and reﬂective
of in vivo efﬁcacy of 4F-PCC-mediated rivaroxaban reversal. This agrees
with results obtained in a study of apixaban reversal in human plasma
ex vivo [41]. Interestingly, in a recent clinical study in which 4 F-PCC re-
versed edoxaban-associated bleeding in healthy volunteers following a
punch biopsy, ETP was also found to correlate well with reversal of
bleedingparameters [42]. Nevertheless, appropriate assays for themon-
itoring of NOACs, preferably quick, simple and that can be used by the
bedside, need to be fully validated.
This study has several strengths and limitations. It was performed
using an established animal model previously used to evaluate both
dabigatran and edoxaban reversal, such that comparisons between
treatments are possible [23,24]. The clinical relevance of this animal
model is also supported by the healthy volunteer study described
above [42], which conﬁrms the preclinical data generated regarding
4F-PCC-mediated edoxaban reversal [24]. This study design best repre-
sents cases where anticoagulant reversal is required prior to urgent sur-
gical procedures; however, given the half-lives of 4 F-PCC coagulation
factors in this rabbit model (2–20 h [24]), comparable plasma levels
would be expected throughout the course of this study, such that the
authors would expect to see similar results irrespective of the timing
of injury relative to administration of 4F-PCC. Furthermore, rabbit
models have been found to be suitablemodels for assessment of FXa in-
hibitors. This is because they are comparable to humans in terms of
in vitro anticoagulation effect of FXa inhibitors [43], and are more sensi-
tive to small molecule FXa inhibitors than mice, rats or dogs [44,45]. In
addition, the use of a randomised design and of both placebo and nega-
tive control groups allowed for a rigorous evaluation of rivaroxaban re-
versal with 4F-PCC. This study was primarily designed to evaluate the
effectiveness of 4F-PCC-mediated reversal of rivaroxaban effects on
bleeding diathesis; safety was not a predeﬁned study endpoint and
wouldneed to be assessed as part of future studies. Published preclinical
studies of dabigatran reversal with 4 F-PCC indicate that 4 F-PCC doses
similar to those used in this study are not associated with a
prothrombotic risk [46]. Finally, it should also be noted that this study
evaluated an off-label use of this 4F-PCC.
In conclusion, the 4 F-PCC evaluated in this study effectively re-
versed the effects on bleeding diathesis induced by administration
of rivaroxaban 150 μg/kg (4 F-PCC dose of 25 IU/kg) and 300 μg/kg
(4F-PCC doses ≥50 IU/kg) in a rabbit model of acute haemorrhage. In
addition, rivaroxaban-induced effects on coagulation parameters were
partially normalised,withWBCT correlating bestwith 4F-PCC-mediated
reversal of rivaroxaban effects on bleeding diathesis. The thrombin
560 E. Herzog et al. / Thrombosis Research 135 (2015) 554–560generation assay was found to be reagent-dependent. The RD reagent-
initiated assay was the most sensitive to in vivo reversal of
rivaroxaban-associated bleeding; peak thrombin generation and
ETP correlated well with reversal of rivaroxaban-induced effects on
bleeding diathesis using these assay conditions. These observations fur-
ther highlight the need for validated assays to monitor NOAC-induced
anticoagulation. While the 4 F-PCC evaluated in this study might be an
option for urgent rivaroxaban reversal, clinical data in rivaroxaban-
treated patients are necessary to conﬁrm these study results.
Conﬂicts of Interest
All authors are employees of CSL Behring GmbH. GD and JM-C own
CSL Behring stock.
Acknowledgements
EH and GDdesigned andmonitored the research study, analysed the
data and wrote the paper; FK, WK, PN and BD performed the experi-
mental work; JM-C conducted the statistical analysis of the data;
Bayer AG provided rivaroxaban; all authors critically reviewed the
manuscript. Medical writing assistance was provided by Chrystelle
Rasamison of Fishawack Communications Ltd and funded by CSL
Behring GmbH.
References
[1] Leadley Jr RJ. Coagulation factor Xa inhibition: biological background and rationale.
Curr Top Med Chem 2001;1:151–9.
[2] Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, et al. In
vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral,
direct Factor Xa inhibitor. J Thromb Haemost 2005;3:514–21.
[3] Bayer Pharma AG. Xarelto – Highlights of Prescribing Information; 2014.
[4] MueckW, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmaco-
dynamic proﬁle of rivaroxaban. Clin Pharmacokinet 2014;53:1–16.
[5] Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new
oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010;30:376–81.
[6] Molenaar PJ, Dinkelaar J, Leyte A. Measuring Rivaroxaban in a clinical laboratory set-
ting, using common coagulation assays, Xa inhibition and thrombin generation. Clin
Chem Lab Med 2012;50:1799–807.
[7] Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring Oral Direct
Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcom-
mittee on Control of Anticoagulation of the Scientiﬁc and Standardisation Committee
of the International Society on Thrombosis and Haemostasis. J Thromb Haemost
2013;11:756–60.
[8] Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J
Med 2011;365:2039–40.
[9] Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N
Engl J Med 2012;366:864–6.
[10] Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.
Dabigatran versus warfarin in patients with atrial ﬁbrillation. N Engl J Med 2009;
361:1139–51.
[11] Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al.
Edoxaban versus warfarin in patients with atrial ﬁbrillation. N Engl J Med 2013;
369:2093–104.
[12] Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.
Apixaban versus warfarin in patients with atrial ﬁbrillation. N Engl J Med 2011;
365:981–92.
[13] Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, HackeW, et al. Rivaroxaban versus
warfarin in nonvalvular atrial ﬁbrillation. N Engl J Med 2011;365:883–91.
[14] Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European
Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in
patients with non-valvular atrial ﬁbrillation. Europace 2013;15:625–51.
[15] Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al.
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J
Hematol 2012;87(Suppl. 1):S141–5.
[16] Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral antico-
agulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Chest 2012;141:e44S–88S.
[17] Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the
anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med 2013;80:
443–51.
[18] Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing new oral anticoag-
ulants in the perioperative and intensive care unit setting. Anesthesiology 2013;118:
1466–74.[19] Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, et al. Management
of major bleeding complications and emergency surgery in patients on long-term
treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: pro-
posals of the working group on perioperative haemostasis (GIHP) – March 2013.
Arch Cardiovasc Dis 2013;106:382–93.
[20] Pollack Jr CV. Managing bleeding in anticoagulated patients in the emergency care
setting. J Emerg Med 2013;45:467–77.
[21] Turpie AG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for
the use of rivaroxaban – an oral, direct factor Xa inhibitor. Thromb Haemost 2012;
108:876–86.
[22] MiesbachW, Seifried E. New direct oral anticoagulants – current therapeutic options
and treatment recommendations for bleeding complications. Thromb Haemost
2012;108:625–32.
[23] Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, et al. Reversal of
dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in
a rabbit model. J Thromb Haemost 2012;10:1841–8.
[24] Herzog E, Kaspereit F, Krege W, Doerr B, Mueller-Cohrs J, Pragst I, et al. Effective re-
versal of edoxaban-associated bleeding with four-factor prothrombin complex con-
centrate in a rabbit model of acute hemorrhage. Anesthesiology 2014. http://dx.doi.
org/10.1097/ALN.0000000000000520 [Epub ahead of print].
[25] C.S.L. Behring. Kcentra® Highlights of Prescribing Information; 2013.
[26] Lawless JF. Statistical models and methods for lifetime data (Section 6.5.2). New
York: John Wiley & Sons; 1982.
[27] Girgis IG, Patel MR, Peters GR, Moore KT, Mahaffey KW, Nessel CC, et al. Population
pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-
valvular atrial ﬁbrillation: results from ROCKET AF. J Clin Pharmacol 2014;54:917–27.
[28] Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A speciﬁc antidote
for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor
Xa. Nat Med 2013;19:446–51.
[29] Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin
complex concentrates (PCCs): what is the evidence? Thromb Haemost 2013;111:
189–98.
[30] Galan AM, Arellano-Rodrigo E, Sanz V, Molina P, Reverter JC, Carne X, et al. Reversal
of the antithrombotic action of rivaroxaban and dabigatran: a clinical study in
healthy volunteers. Blood (ASH Annual Meeting Abstracts), 120; 2012. p. 2261.
[31] Godier A,Miclot A, Le Bonniec B, DurandM, Fischer AM, Emmerich J, et al. Evaluation
of prothrombin complex concentrate and recombinant activated factor VII to reverse
rivaroxaban in a rabbit model. Anesthesiology 2012;116:94–102.
[32] Pillitteri D, Pilgrimm-Thorp A-K, Krause M, Scholz T, Schwerdtfeger R, Behrendt T, et al.
Antidotal effects of non-speciﬁc reversal agents on anticoagulant-induced inhibition of
thrombin generation. Blood (ASH Annual Meeting Abstracts), 120; 2012. p. 2273.
[33] Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of
rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized,
placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573–9.
[34] Levi M, Moore KT, Castillejos CF, Kubitza D, Berkowitz SD, Goldhaber SZ, et al. Com-
parison of three-factor and four-factor prothrombin complex concentrates regarding
reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb
Haemost 2014;12:1428–36.
[35] Perzborn E, Heitmeier S, Laux V, Buchmuller A. Reversal of rivaroxaban-induced
anticoagulation with prothrombin complex concentrate, activated prothrombin
complex concentrate and recombinant activated factor VII in vitro. Thromb Res
2014;133:671–81.
[36] Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman HJ, Leyte A. In vitro as-
sessment, using thrombin generation, of the applicability of prothrombin complex
concentrate as an antidote for Rivaroxaban. J Thromb Haemost 2013;11:1111–8.
[37] Korber MK, Langer E, Ziemer S, Perzborn E, Gericke C, Heymann C. Measurement
and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an
in vitro study. Clin Appl Thromb Hemost 2014;20:735–40.
[38] Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M,
et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used co-
agulation assays. J Thromb Haemost 2011;9:133–9.
[39] SamamaMM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, et al. Assess-
ment of laboratory assays to measure rivaroxaban–an oral, direct factor Xa inhibitor.
Thromb Haemost 2010;103:815–25.
[40] Zhou W, Zorn M, Nawroth P, Butehorn U, Perzborn E, Heitmeier S, et al. Hemostatic
therapy in experimental intracerebral hemorrhage associated with rivaroxaban.
Stroke 2013;44:771–8.
[41] Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Roquer J, Reverter JC, Sanz VV,
et al. Reversal of apixaban induced alterations in hemostasis by different coagulation
factor concentrates: signiﬁcance of studies in vitro with circulating human blood.
PLoS One 2013;8:e78696.
[42] Zahir H, Brown KS, Vandell A, Desai M, Maa JF, Dishy V, et al. Edoxaban Effects on
Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex
Concentrate. Circulation 2015;131:82–90.
[43] Zhang D, He K, Raghavan N, Wang L, Crain EJ, He B, et al. Metabolism, pharmacoki-
netics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. J
Thromb Thrombolysis 2010;29:70–80.
[44] Hara T, Yokoyama A, Morishima Y, Kunitada S. Species differences in anticoagulant
and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb
Res 1995;80:99–104.
[45] Wong PC, Pinto DJ, Knabb RM. Nonpeptide factor Xa inhibitors: DPC423, a highly po-
tent and orally bioavailable pyrazole antithrombotic agent. Cardiovasc Drug Rev
2002;20:137–52.
[46] Herzog E, Kaspereit FJ, Krege W, Doerr B, van Ryn J, Dickneite G, et al. Thrombotic
safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal
in a rabbit model. Thromb Res 2014;134:729–36.
